About Third Pole Therapeutics
Third Pole Therapeutics is a Healthcare company based in Boston (United States) founded in 2014 by David Zapol. Third Pole Therapeutics has raised $87.6 million across 5 funding rounds from investors including Avenue Capital Group. Its chief executive, as recorded, is David Zapol. Third Pole Therapeutics offers products and services including eNOfit and Inhaled Nitric Oxide Platform. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is Third Pole, Inc. Its competitors include Vyaire, Valencia Technologies and Rox Medical; 3 of its 3 listed competitors have raised funding.
Company details
Developer of devices for cardiopulmonary therapies. The company is developing a device offering nitric oxide (NO) from iridium electrodes for infant acute pulmonary hypertension, heart, and lung therapies. The inhaled nitric oxide therapy delivery system relaxes the blood vessels lowering the blood pressure.
- Total Equity Funding$87.6M (USD)
in 5 rounds
- Latest Funding Round$16.85M (USD), Series B
Mar 2024
- Investors
Products & Services of Third Pole Therapeutics
Third Pole Therapeutics offers a comprehensive portfolio of products and services, including eNOfit and Inhaled Nitric Oxide Platform.
Portable system for delivering inhaled nitric oxide therapy.
Wearable device for on-demand nitric oxide delivery in treatments.
Funding Insights of Third Pole Therapeutics
Third Pole Therapeutics has successfully raised a total of $87.6M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $16.85 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.6M
- Total Rounds 5
- Last Round Series B — $16.85M
- First Round $13.75M
(Jan 2018)
- Investors Count 1
All 5 funding rounds of Third Pole Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $16.85M | Series B | – | – | – |
| Dec 2022 | $32M | Series B | – | – | – |
| Feb 2022 | $25M | Series B | – | – | – |
| Apr 2021 | $15M | Debt – Conventional | – | – | |
| Jan 2018 | $13.75M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Third Pole Therapeutics
Third Pole Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Avenue Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investments in distressed debt and securities are managed globally. | 1995 | avenuecapital.com | New York, United States |
Investor details for Third Pole Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Third Pole Therapeutics
5 people are tracked at Third Pole Therapeutics (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
David Zapol | Co-Founder & CEO | Leadership |
Bill Athenson | Chief Executive Officer | Leadership |
Tony Raymond | Vice President of Quality Assurance and Regulatory Affairs | Leadership |
Elizabeth Holmberg | Chief Financial Officer | Leadership |
Adam Young | Senior Manager, Mechanical Engineering | Team |
Complete people profiles for Third Pole Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Third Pole Therapeutics
3 dated milestones of Third Pole Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Third Pole Therapeutics is founded.
- Funding First funding round of $13.8M.
- Funding Latest funding round, Series B, of $16.9M.
Competitors of Third Pole Therapeutics
Third Pole Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Vyaire, Valencia Technologies and Rox Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vyaire.com | 2016 | Illinois, United States | $31.53M | 7 | Respiratory devices for diagnostics, ventilation, and patient monitoring are developed. | |
| valenciatechnologies.com | 2011 | Santa Clarita, United States | $54.97M | A coin-sized neuromodulation device for hypertension treatment is developed. | ||
| roxmedical.com | 2004 | San Clemente, United States | $101.1M | 6 | Develops interventional vascular therapies. |
Detailed competitors of Third Pole Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Third Pole Therapeutics
The website of Third Pole Therapeutics (pole3.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 14.5% vs previous month
Top companies in Pulmonology
3 companies that operate in the same segment as Third Pole Therapeutics (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Third Pole Therapeutics
Complete news archive for Third Pole Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Third Pole Therapeutics
Third Pole Therapeutics was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Third Pole Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
David Zapol is the CEO of Third Pole Therapeutics, as recorded in our data. They have also founded this company.
Third Pole Therapeutics is a funded company, having raised a total of $87.6M across 5 funding rounds to date. The company's 1st funding round was a Series B of $13.75M, raised on Jan 2018.
Developer of devices for cardiopulmonary therapies. The company is developing a device offering nitric oxide (NO) from iridium electrodes for infant acute pulmonary hypertension, heart, and lung therapies. The inhaled nitric oxide therapy delivery system relaxes the blood vessels lowering the blood pressure.
Third Pole Therapeutics's top competitors include Valencia Technologies, Vyaire and Rox Medical.
Third Pole Therapeutics offers eNOfit and Inhaled Nitric Oxide Platform.
Third Pole Therapeutics has 1 investor. Key investors include Avenue Capital Group.
Third Pole Therapeutics operates through Third Pole, Inc..